Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

470.63 +6.07 (+1.31%)
Streaming Delayed Price Updated: 11:12 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
54 55 Next >
Got $5,000? Buy and Hold These Fast-Growing Stocks for Years
These companies have doubled their sales within the past five years. 
Via The Motley Fool
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now
These stocks should hold up quite well regardless of what happens with the U.S. economy. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Marching Higher Today
This gene-editing stock has been heating up over the past week. 
Via The Motley Fool
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before. 
Via Investor's Business Daily
Is CRISPR Therapeutics Stock a Buy Now?
The biotech could soon be a commercial-stage company. 
Via The Motley Fool
CRISPR Stock: Bull vs. Bear
CRISPR's first approved product may be right around the corner. 
Via The Motley Fool
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
Which Stocks Pass Warren Buffett's $10,000 Test?
Buffett's recent CNBC interview raises an interesting question. 
Via The Motley Fool
Prediction: These Will Be 3 of the Biggest Monster Stocks of the Decade
They're already highly successful. But there's a lot more room to run. 
Via The Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Records 52-Week High Thursday Morning
Via Investor Brand Network
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
Massive drivers of fresh earnings are drawing closer, and risks are declining. 
Via The Motley Fool
Moderna, ConocoPhillips, Vertex Pharmaceuticals And This ETF: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JP Morgan Private Bank named iShares Preferred and Income Securities ETF (NYSE: PFF) as her 
Via Benzinga
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
Vertex to Announce First Quarter 2023 Financial Results on May 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
My 5 Top Stocks to Buy in April
These stocks share one primary common denominator -- great growth prospects. 
Via The Motley Fool
2 Winning Stocks That Could Turn $10,000 into $50,000 by 2030
These stocks have growth stories that could supercharge returns over the long run. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in a New Bull Market
These stocks have what it takes to soar if and when a new bull market begins. 
Via The Motley Fool
Nasdaq Bear Market: 5 Astonishing Growth Stocks You'll Regret Not Buying on the Dip
A 33% plunge in the Nasdaq Composite is the perfect excuse for opportunistic investors to pounce on discounted growth stocks. 
Via The Motley Fool
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
2 Once-in-a-Decade Buying Opportunities in a Growth Stock Bear Market
These stocks have growth stories that investors might find too compelling to overlook. 
Via The Motley Fool
A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right Now
Don't let these superior stocks pass you by. 
Via The Motley Fool
2 Smartest Growth Stocks to Buy Without Hesitation Right Now
A turbulent market is still full of opportunity for shrewd investors. 
Via The Motley Fool
Where to Invest $2,500 Right Now
Even another bear market doesn't need to deter investors with the appropriate buy-and-hold horizon. 
Via The Motley Fool
2 Top Stocks to Buy Before the Next Nasdaq Bull Market
Tough market conditions will eventually give way to the next bull run on stocks. 
Via The Motley Fool
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.